Hypocalcaemia

Meet the patient

Twenty-four hours after a total thyroidectomy for papillary cancer, a 38-year-old woman rings the bell complaining that her fingertips and lips are tingling, and her corrected calcium is 1.6 mmol/L.^[14]

The first question is the one that decides her safe discharge: what do you give, and what must you check before it will work? Give the calcium — but if her magnesium is low the calcium may not rise: hypomagnesaemia inhibits PTH secretion and produces hypocalcaemia resistant to calcium supplementation, and postoperative magnesium is a recognised predictor of post-thyroidectomy hypocalcaemia.^[7][14]

Meet the calcium — and the albumin trap

Hypocalcaemia is defined as a serum calcium below 8 mg/dL (2.12 mmol/L).^[1] Calcium circulates bound to albumin, so changes in albumin concentration directly affect total calcium measurements; correction factors are therefore frequently used, the most widely used being the equation described by Payne and colleagues in 1973.^[15] The practical rule used in clinical practice is:^[12]

Corrected total Ca (mg/dL) = measured total Ca + 0.8 × (4.0 − albumin in g/dL) — equivalent to adding 0.02 mmol/L for every 1 g/L that albumin is below 40 g/L. ^[12]

Worked example: a patient with measured calcium 1.90 mmol/L (7.6 mg/dL) and albumin 2.5 g/dL (25 g/L) has a corrected calcium of 7.6 + 0.8 × (4.0 − 2.5) = 8.8 mg/dL (about 2.20 mmol/L) — borderline rather than profoundly low. Adjusting for albumin is not optional bookkeeping: in a classic series, markedly abnormal total calcium values were reduced from 115 patients to 24 after albumin adjustment, and three patients had significant hypercalcaemia masked by hypoalbuminaemia. Adjustment is essential to detect abnormal values and to assess change in an individual.^[11] When doubt exists, ionised calcium measured directly is the standard against which adjusted-calcium equations are judged.^[15]

Severity sets the tempo. The Society for Endocrinology emergency guidance defines severe hypocalcaemia as a serum calcium under 1.9 mmol/L and/or symptomatic disease at any level below the reference range — a medical emergency requiring immediate IV calcium with ECG monitoring.^[13] Below that threshold, management is guided by symptoms and by the trajectory of serial calcium measurements, which are among the strongest predictors of outcome after thyroid surgery.^[14]

The pivotal diagnostic step — and the most frequently missed — is to measure PTH, and magnesium alongside it. Hypoparathyroidism is defined by inadequately low circulating PTH producing low calcium with increased phosphate; a "normal-range" PTH in the face of hypocalcaemia is inappropriately low and means gland failure, while an appropriately high PTH directs the search to the non-PTH-mediated causes.^[1][2] Magnesium is the silent trap: hypomagnesaemia acts through the calcium-sensing receptor to inhibit PTH secretion, generating hypocalcaemia that is resistant to calcium supplementation.^[7]

Three axes that sort the differential

Hypocalcaemia is classified along three axes that together determine the differential, the urgency and the treatment. ^[1]

^{[1] [2] [4] [13]}

Enlarge

How common, and where you meet it

The commonest cause of hypocalcaemia depends on where the patient is encountered. Hypoparathyroidism is most commonly seen after neck surgery, which accounts for approximately 75 percent of cases, with the remaining quarter due to non-surgical causes — autoimmune disease, genetic causes, infiltrative diseases, mineral deposition and magnesium abnormalities.^[4] Within the surgical group, inadvertent removal of, or injury to, the parathyroid glands during neck surgery is the single commonest mechanism, followed by genetic, idiopathic and autoimmune aetiologies.^[2]

Post-thyroidectomy hypocalcaemia is the best-characterised iatrogenic cause. A systematic review and meta-analysis of 115 observational studies reported a median incidence of transient hypocalcaemia of 27 percent (interquartile range 19 to 38 percent) and of permanent hypocalcaemia of 1 percent (range 0 to 3 percent).^[14] Independent predictors include perioperative PTH, preoperative calcium, preoperative 25-hydroxyvitamin D and postoperative magnesium; clinical predictors include female sex, surgery for recurrent goitre, Graves' disease, reoperation for bleeding and inadvertent parathyroid excision. A calcium level under 1.88 mmol/L at 24 hours after surgery, identification of fewer than two parathyroid glands at operation and heavier thyroid specimens predicted permanent hypocalcaemia.^[14]

^{[1] [13] [14] [4]}

Beyond surgery, the high-risk groups the examiner expects you to name come directly from the non-surgical cause spectrum: autoimmune disease, genetic causes (including DiGeorge syndrome — 22q11.2 deletion — which can present for the first time in adulthood or pregnancy), infiltrative diseases, mineral deposition, and abnormalities in serum magnesium (classically with chronic proton-pump-inhibitor use, which impairs intestinal magnesium absorption through TRPM6/TRPM7).^[4][5][7][9]

Why low calcium makes nerves fire — the homeostatic loop

Calcium homeostasis is governed by the PTH–vitamin D axis. In health, PTH and activated vitamin D defend the serum calcium; in chronic kidney disease the classic sequence is a deficit of calcitriol synthesis and retention of phosphorus, so serum calcium falls and PTH is stimulated, producing high-turnover bone disease (osteitis fibrosa) at one extreme and adynamic low-turnover bone disease at the other.^[12] When PTH itself is missing or ineffective, calcium falls while phosphate rises — the biochemical signature of hypoparathyroidism.^[2] Magnesium sits on this loop too: severe hypomagnesaemia increases calcium-sensing-receptor activity and thereby inhibits PTH secretion.^[7]

Enlarge

At the molecular level, the exemplar of target-organ resistance is pseudohypoparathyroidism, caused by mutations and/or epigenetic changes at the complex GNAS locus: target tissues resist the biological actions of PTH, so PTH is elevated while calcium is low and phosphate high. Bone in PHP shows only partial sensitivity to PTH, producing heterogeneous — even regionally variable — skeletal responses, with higher bone mineral density in type 1A and decreased bone mass or osteosclerosis reported in type 1B.^[8]

The mechanisms of the major causes are exam classics. Hypomagnesaemia (classically from long-term proton-pump-inhibitor use, which interferes with active cellular magnesium transport regulated by the TRPM6 and TRPM7 channels) acts at the calcium-sensing receptor: dissociation of magnesium from the alpha subunit of the G protein increases receptor activity, inhibiting PTH secretion and producing hypocalcaemia resistant to calcium supplementation — with a parallel, potassium-resistant hypokalaemia driven by ROMK unblocking.^[7] Chronic kidney disease lowers calcium through deficient calcitriol synthesis and phosphorus retention, which secondarily stimulates PTH and drives high-turnover bone disease.^[12]

The face of an irritable nerve

The clinical face of hypocalcaemia is neuromuscular irritability. The symptom complex described in the major reviews is tingling (perioral and distal paraesthesia), muscle cramps and seizures, with manifestations that may involve almost any organ system and may range from asymptomatic to life-threatening.^[1][2] Hypoparathyroidism in particular is a multisystem disease: long-term complications include ectopic (brain) calcification, nephrocalcinosis, nephrolithiasis and renal impairment, in addition to respiratory, cardiac and neurological manifestations.^[5]

Symptom tempo tracks severity: asymptomatic biochemical disease is common (and in the newborn period usually needs only monitoring), while symptomatic tetany or convulsion marks the emergency end of the spectrum requiring immediate parenteral calcium.^[13][17]

^{[1] [2] [13]}

Multisystem involvement is the reason hypocalcaemia is examined across every specialty. Beyond neuromuscular symptoms, hypoparathyroidism causes respiratory, cardiac and neurological manifestations, and its long-term complications — ectopic calcification (including brain calcification), nephrocalcinosis, nephrolithiasis and renal impairment — are largely preventable with adequate calcium and active vitamin D replacement.^[2][5] Conventional therapy itself adds complications: it does not fully replace PTH's functions and can cause hypocalcaemia, hypercalcaemia and increased urinary calcium excretion acutely, and nephrocalcinosis, kidney stones and brain calcifications long-term.^[2]

Atypical presentations are deliberately examined. The post-thyroidectomy patient may be asymptomatic at 24 hours yet declared by her calcium trend — a level under 1.88 mmol/L at 24 hours independently predicts permanent hypocalcaemia.^[14] The newborn may present with non-specific features, and late-onset neonatal hypocalcaemia is generally symptomatic, developing after the first 72 hours and toward the end of the first week of life.^[17] The pregnant patient may carry unsuspected DiGeorge syndrome (22q11.2 deletion) presenting as chronic asymptomatic hypocalcaemia with suppressed PTH — a reminder that genetic aetiologies can declare themselves decades late.^[9]

The PTH-phosphate decoder

The differential is best organised by the PTH-based framework, because the PTH result is the single most powerful branch point in the work-up. The key is to interpret PTH relative to the calcium — a "normal-range" PTH in the face of hypocalcaemia is inappropriately low and means parathyroid gland failure, not health.^[1][4]

^{[1] [4] [8] [12] [16]}

Two pitfalls deserve explicit mention. The albumin trap: unadjusted total calcium misclassifies patients — in the classic series only 24 of 115 patients with markedly abnormal total calcium remained abnormal after albumin adjustment, and significant hypercalcaemia can be masked by hypoalbuminaemia; conversely, a low total calcium with normal ionised calcium needs adjustment, not treatment.^[11] The magnesium trap: hypomagnesaemia produces hypocalcaemia resistant to calcium supplementation by inhibiting PTH secretion, and often coexists with hypokalaemia that is itself resistant to potassium supplementation — no amount of calcium or potassium will stick until magnesium is corrected.^[7]

The rare genetic end-organ resistance group is small but high-yield. Pseudohypoparathyroidism (PHP) is caused by mutations and/or epigenetic changes at the complex GNAS locus and is characterised by hypocalcaemia, hyperphosphataemia and an elevated PTH concentration secondary to resistance of target tissues to the biological actions of PTH; it is divided into several subtypes with different yet overlapping phenotypes.^[8] Distinguishing PHP from primary hypoparathyroidism is the PTH level: elevated in PHP (the gland works, the target tissues resist), inadequately low in gland failure.^[2][8]

The bedside round — confirm, screen, escalate

The bedside assessment has three goals: confirm neuromuscular irritability, screen for the underlying cause, and detect the emergency that needs IV calcium. The history centres on tingling, muscle cramps and any seizure activity; the examination screens for a neck surgery scar (post-surgical hypoparathyroidism is the most frequent cause), signs of CKD, and the drug history — above all chronic proton-pump-inhibitor use as a cause of hypomagnesaemia-related refractory hypocalcaemia.^[1][4][7]

Severity is assessed against the emergency threshold. The Society for Endocrinology guidance is explicit: severe hypocalcaemia is a serum calcium under 1.9 mmol/L and/or symptomatic disease at any level below the reference range, and it is a medical emergency. Initial treatment is 10 to 20 mL of 10 percent calcium gluconate in 50 to 100 mL of 5 percent dextrose, given intravenously over 10 minutes with ECG monitoring, repeated until the patient is asymptomatic.^[13] Calcium chloride is an alternative but is more irritant to veins and should only be given via a central line.^[13]

In the post-thyroidectomy patient, the protocolised assessment is part of the surgical pathway: hypocalcaemia is common after thyroidectomy, accurate prediction and appropriate management reduce morbidity and hospital stay, and the 24-hour calcium level (under 1.88 mmol/L predicting permanent disease) with perioperative PTH, preoperative calcium, preoperative 25-hydroxyvitamin D and postoperative magnesium are the predictors that matter.^[14]

The first blood draw that cracks the case

The first-line panel for any hypocalcaemia is short, focused, and answers the differential in one blood draw: total calcium (with albumin for adjustment), magnesium, PTH and phosphate, renal function and 25-hydroxyvitamin D where the setting demands it.^[1][4]

^{[1] [4] [7] [12] [14]}

The PTH-phosphate decoder is the single most examinable pattern in the work-up. Low (or inappropriately normal) PTH with high phosphate = hypoparathyroidism — post-surgical (most common), genetic, idiopathic, autoimmune, infiltrative, or magnesium-related.^[2][4] Elevated PTH with hypocalcaemia and hyperphosphataemia = target-tissue resistance (pseudohypoparathyroidism, GNAS locus).^[8] Elevated PTH that is an appropriate secondary rise = non-PTH-mediated hypocalcaemia, where a more comprehensive cause search is needed for appropriate treatment.^[1]

Second-line tests are guided by the differential and are not routine. Genetic testing is decisive when a genetic aetiology is suspected — in the index DiGeorge case, genetic testing confirmed a 22q11.2 microdeletion in a pregnant woman with chronic hypocalcaemia and suppressed PTH, after biochemical evaluation had localised the problem to primary hypoparathyroidism.^[9]

Urinary calcium is part of chronic hypoparathyroidism monitoring — conventional therapy explicitly aims to normalise urine calcium levels, because sustained hypercalciuria drives nephrocalcinosis, nephrolithiasis and renal impairment.^[4][5] In the PaTHway trial of palopegteriparatide, mean 24-hour urine calcium fell from 376 mg/day at baseline to 195 mg/day at week 52 — hormone replacement, unlike conventional therapy, restores urinary calcium conservation.^[6]

Self-test — A 62-year-old woman three days after total thyroidectomy has corrected calcium 1.55 mmol/L, phosphate 1.9 mmol/L (high), PTH 0.8 pg/mL (low), magnesium 0.45 mmol/L. What is the diagnosis and first action?ShowHide

Post-surgical hypoparathyroidism — low PTH with high phosphate after neck surgery, the most frequent cause of hypocalcaemia.^[1][2] First action: her calcium is under 1.9 mmol/L, which is severe hypocalcaemia — a medical emergency: give IV calcium gluconate 10 percent, 10 to 20 mL in 50 to 100 mL of 5 percent dextrose over 10 minutes with ECG monitoring, repeated until asymptomatic, followed by a continuous infusion (100 mL of 10 percent calcium gluconate diluted in 1 L of normal saline or 5 percent dextrose, at 50 to 100 mL/hour).^[13] The high phosphate reflects the loss of PTH action — inadequate PTH produces low calcium with increased phosphate.^[2] Magnesium must be checked and corrected, because hypomagnesaemia makes hypocalcaemia resistant to calcium supplementation.^[7]

^[13]

The first fifteen minutes — calcium, with the ECG on

The acute severe patient — a serum calcium under 1.9 mmol/L and/or symptomatic at any level below the reference range — is a medical emergency and needs immediate IV calcium with ECG monitoring.^[13] The regimen from the Society for Endocrinology emergency guidance, verbatim in substance: give 10 to 20 mL of 10 percent calcium gluconate in 50 to 100 mL of 5 percent dextrose intravenously over 10 minutes with ECG monitoring; this can be repeated until the patient is asymptomatic. It should be followed by a calcium gluconate infusion: dilute 100 mL of 10 percent calcium gluconate (10 vials) in 1 L of normal saline or 5 percent dextrose and infuse at 50 to 100 mL/hour, titrated to achieve normocalcaemia and continued until treatment of the underlying cause has taken effect.^[13]

Enlarge

The chronic ladder — low-normal, not mid-normal

The chronic management ladder is built around two principles: conventional therapy with calcium and active vitamin D analogue therapy, aiming to maintain serum calcium in the low-normal or just below the normal reference range and to normalise serum phosphorus, magnesium and urine calcium levels.^[4] In hypoparathyroidism the active form matters: conventional treatment is activated vitamin D and/or calcium supplements — native vitamin D alone does not replace missing PTH-dependent activation.^[2] In CKD, the rationale is explicit — a deficit of calcitriol synthesis sits at the head of the mineral-metabolism cascade, so active vitamin D analogues, intestinal phosphorus binders and calcimimetics are the titration tools.^[12]

^{[1] [2] [4] [5] [6]}

The post-thyroidectomy patient deserves a protocolised pathway. The 2014 systematic review and meta-analysis of 115 observational studies underpins modern risk stratification: perioperative PTH, preoperative calcium, preoperative 25-hydroxyvitamin D and postoperative magnesium are biochemical predictors, and female sex, Graves' disease, recurrent-goitre surgery, reoperation for bleeding, inadvertent parathyroid excision and parathyroid autotransplantation were associated with transient hypocalcaemia in meta-analysis. A 24-hour calcium under 1.88 mmol/L, fewer than two parathyroid glands identified, reoperation for bleeding, Graves' disease and heavier specimens independently predicted permanent hypocalcaemia. Median incidence: transient 27 percent (IQR 19 to 38), permanent 1 percent (0 to 3).^[14]

Monitoring is intrinsic to the guideline approach — the revised ESE guideline sets out explicit recommendations for the diagnosis, management and monitoring of chronic hypoparathyroidism in adults^[3], and the international guideline frames the targets: serum calcium low-normal or just below the reference range, with phosphorus, magnesium and urine calcium normalised.^[4]

The subtypes that bite

Post-surgical hypoparathyroidism is the prototype and the commonest cause. The mechanism is inadvertent removal of, or injury to, the parathyroid glands during neck surgery; it accounts for approximately 75 percent of hypoparathyroidism, the remainder being non-surgical.^[2][4] Risk is concentrated in female patients, Graves' disease, recurrent-goitre surgery, reoperation for bleeding, inadvertent parathyroid excision and cases requiring parathyroid autotransplantation; preoperative 25-hydroxyvitamin D deficiency and low preoperative calcium raise risk further.^[14]

Autoimmune, idiopathic and infiltrative hypoparathyroidism form the non-surgical core: after neck surgery, the ranked aetiologies are genetic, idiopathic and autoimmune, with infiltrative diseases and mineral deposition also recognised, plus abnormalities in serum magnesium.^[2][5]

DiGeorge syndrome (22q11.2 deletion syndrome) is a common microdeletion disorder whose highly variable features often delay diagnosis until adulthood — the index case presented as chronic asymptomatic hypocalcaemia in the third trimester with suppressed PTH, and genetic testing confirmed the 22q11.2 microdeletion. In the absence of hallmark findings such as congenital heart defects or dysmorphic features, the diagnosis is easily missed, which is the exam point: think 22q11.2 in unexplained hypoparathyroidism at any age, including pregnancy.^[9]

Hypocalcaemia of CKD follows the classic sequence: a deficit of calcitriol synthesis and retention of phosphorus, so serum calcium decreases and PTH is stimulated, producing high-turnover bone disease (osteitis fibrosa) at one pole and adynamic low-turnover bone disease at the other, with soft-tissue and vascular deposition linking bone disease to vascular calcification. Management is by titration of intestinal phosphorus binders, vitamin D analogs and calcimimetics, guided by serial calcium and phosphorus measurement.^[12]

Hungry bone syndrome follows parathyroidectomy for medication-refractory secondary hyperparathyroidism in dialysis patients: a narrative review puts the risk at 20 to 70 percent — severe sustained hypocalcemia requiring intensive care and prolonged hospitalization. Accurate preoperative risk stratification using biochemical markers and validated prediction tools is critical for optimal preventive management.^[16]

Hypomagnesaemia-induced hypocalcaemia is the silent cause of refractory hypocalcaemia. The best-characterised offender is long-term proton-pump-inhibitor treatment, which changes intestinal luminal pH and interferes with active cellular magnesium transport regulated by the TRPM6 and TRPM7 channels. The magnesium depletion then acts on the calcium-sensing receptor — dissociation of magnesium from the alpha subunit of the G protein increases its activity, leading to inhibition of PTH secretion and hypocalcaemia resistant to calcium supplementation, with a parallel hypokalaemia resistant to potassium supplementation (ROMK unblocking).^[7] The rule: if hypocalcaemia is refractory, check and correct magnesium.^[7]

Pseudohypoparathyroidism is the exam-classic end-organ resistance state: hypocalcaemia, hyperphosphataemia and an elevated PTH concentration secondary to resistance of target tissues to the biological actions of PTH, caused by mutations and/or epigenetic changes at the complex GNAS locus. Bone phenotypes are highly variable — higher bone mineral density in type 1A, but decreased bone mass, osteosclerosis and osteitis fibrosa cystica in type 1B — because bone retains only partial sensitivity to PTH.^[8]

Drug-induced hypocalcaemia rounds out the high-yield scenarios. The archetype is the proton pump inhibitor: chronic use may lead to life-threatening electrolyte disorders — hypomagnesaemia with secondary hypocalcaemia and hypokalaemia, both resistant to simple replacement.^[7] Magnesium-wasting from any cause enters the same final common pathway of PTH inhibition.^[5][7]

How hypocalcaemic patients come to harm

The acute life-threatening complications are the reason severe hypocalcaemia is a medical emergency: clinical manifestations may range from asymptomatic to life-threatening conditions, and the emergency threshold — calcium under 1.9 mmol/L and/or symptomatic disease — exists precisely to trigger immediate IV calcium.^[1][13] The central nervous system complications of chronic untreated hypoparathyroidism include brain (ectopic) calcification, alongside respiratory, cardiac and neurological manifestations.^[2][5]

The complications of treatment are dominated by hypercalciuria: conventional therapy does not fully replace the functions of PTH and leads to increased urinary calcium excretion short-term and nephrocalcinosis, kidney stones and renal impairment long-term — the reason the chronic target is low-normal calcium with normalised urine calcium, and the reason PTH replacement (which normalises urine calcium) exists.^[2][4][5] The pitfall of treating without correcting magnesium is refractory hypocalcaemia — hypomagnesaemia makes calcium supplementation futile by inhibiting PTH secretion.^[7]

The surgical pitfall of missing post-operative hypocalcaemia is avoidable: accurate prediction and appropriate management reduce morbidity and hospital stay, and the validated predictors (perioperative PTH, preoperative calcium and 25-hydroxyvitamin D, postoperative magnesium, the 24-hour calcium level) are all available on the first postoperative day.^[14]

Prognosis, disposition, and the target that sets both

Acute hypocalcaemia is treated with intravenous calcium infusion — essential to raise calcium levels and resolve or minimise symptoms — while the underlying cause is addressed.^[1] Post-surgical transient hypocalcaemia is the expected course in about a quarter of thyroidectomy patients (median 27 percent), with permanent disease in about 1 percent; the 24-hour calcium and perioperative PTH stratify who recovers.^[14] Chronic hypoparathyroidism on conventional therapy lives with fluctuations, pill burden and renal risk — which PTH replacement therapy addresses: it achieves normal serum calcium, lowers phosphate, reduces pill burden and improves quality of life, with palopegteriparatide now approved as PTH replacement therapy.^[5]

Disposition follows severity. Severe hypocalcaemia (under 1.9 mmol/L and/or symptomatic) is a medical emergency: IV calcium gluconate over 10 minutes with ECG monitoring, then infusion, under continuous observation.^[13] Asymptomatic or chronic hypocalcaemia is managed with oral calcium and/or vitamin D supplementation — the most frequently used treatment of chronic hypocalcaemia.^[1] Endocrinology referral is indicated for non-surgical aetiologies, refractory or recurrent disease, and candidates for PTH-replacement therapy, where strict selection is necessary because of the high cost.^[1][5]

Special Populations

Neonatal hypocalcaemia is divided by timing. Early-onset disease is generally asymptomatic, so screening at the 24th and 48th hour after birth is warranted for infants at high risk; late-onset hypocalcaemia generally develops after the first 72 hours and toward the end of the first week of life and is generally symptomatic. The commonest causes of late-onset disease are excessive phosphate intake, hypomagnesemia, hypoparathyroidism and vitamin D deficiency. Definitions for term infants and preterm infants over 1500 g: total serum calcium under 8 mg/dL (2 mmol/L) or ionised calcium under 4.4 mg/dL (1.1 mmol/L). Treatment is etiological, with calcium replacement as the cornerstone: elemental calcium 40 to 80 mg/kg/day for asymptomatic newborns, and elemental calcium 10 to 20 mg/kg (1 to 2 mL/kg/dose of 10 percent calcium gluconate) as a slow intravenous infusion for tetany or hypocalcaemic convulsion.^[17]

Pregnancy and lactation demand close biochemical monitoring. The index lesson comes from the DiGeorge-in-pregnancy case: a woman with chronic asymptomatic hypocalcaemia, suppressed PTH and confirmed 22q11.2 microdeletion was managed with moderate-dose cholecalciferol and oral calcium supplements — activated vitamin D analogues were not needed as endogenous 1,25-dihydroxyvitamin D was adequate — and with close biochemical monitoring maternal calcium remained within the target range and she delivered a healthy infant.^[9]

The CKD and dialysis patient follows the mineral-metabolism cascade — calcitriol-synthesis deficit with phosphorus retention — and management proceeds by titration of intestinal phosphorus binders, vitamin D analogs and calcimimetics, with regular calcium and phosphorus measurement decisive during titration.^[12] After parathyroidectomy for secondary hyperparathyroidism, anticipate hungry bone syndrome in 20 to 70 percent — severe sustained hypocalcaemia needing intensive care — and risk-stratify preoperatively with bone-turnover markers and validated prediction tools.^[16]

Evidence, Guidelines & Regional Differences

The 2022 international hypoparathyroidism guideline and the revised 2025 European Society of Endocrinology guideline establish the modern framework for chronic disease: conventional therapy aiming for low-normal calcium with normalised phosphorus, magnesium and urine calcium^[3][4], with PTH replacement for selected patients. The PaTHway trial (52 weeks) of palopegteriparatide (TransCon PTH), administered once daily, showed sustained efficacy, safety and tolerability: 81 percent of participants met the multicomponent endpoint — normal serum calcium (8.3 to 10.6 mg/dL) plus independence from conventional therapy (no more than 600 mg/day elemental calcium and no active vitamin D) — 95 percent achieved independence from conventional therapy, none required active vitamin D, patient-reported quality of life, physical functioning and well-being improved, and 24-hour urine calcium fell from 376 to 195 mg/day.^[6]

^{[1] [13] [1] [1]}

Controversies and evolving evidence include the calcium level at which asymptomatic newborns should be treated (consensus exists for symptomatic cases; the threshold and options remain controversial for asymptomatic infants)^[17], the optimal target for urine calcium on conventional therapy^[4], and who qualifies for PTH replacement — the international guidelines continue to recognise the need for more research to optimise care, and emerging therapies are still developing.^[2][5]

Exam Pearls

Ward-round test — three stems, thirty seconds each

Stem 1 — the woman from the top of the topic (answer)ShowHide

Twenty-four hours after a total thyroidectomy she has perioral and fingertip tingling and corrected calcium 1.6 mmol/L. What do you give, and what must you check before it will work? Model: This is post-surgical hypoparathyroidism — inadvertent removal of, or injury to, the parathyroid glands during neck surgery, the most frequent cause.^[2] Her calcium is under 1.9 mmol/L, so this is severe hypocalcaemia — a medical emergency: IV calcium gluconate 10 percent, 10 to 20 mL in 50 to 100 mL of 5 percent dextrose over 10 minutes with ECG monitoring, repeated until asymptomatic, followed by the infusion regimen (100 mL of 10 percent gluconate in 1 L at 50 to 100 mL/hour); calcium chloride only via a central line.^[13] And check the magnesium and the 24-hour calcium trend — postoperative magnesium is a predictor of post-thyroidectomy hypocalcaemia, and hypomagnesaemia makes calcium supplementation futile by inhibiting PTH secretion.^[7][14]

Stem 2 — the calcium that will not rise (answer)ShowHide

You have given repeated boluses of IV calcium gluconate for severe hypocalcaemia and the corrected calcium barely moves; the patient is still symptomatic. What is the missing step? Model: Check the magnesium — and the drug chart for a proton pump inhibitor. Long-term PPI treatment impairs intestinal magnesium absorption (TRPM6/TRPM7), and the resulting hypomagnesaemia acts on the calcium-sensing receptor to inhibit PTH secretion, producing hypocalcaemia resistant to calcium supplementation; the accompanying hypokalaemia is likewise resistant to potassium until magnesium is corrected.^[7]

Stem 3 — high PTH in a hypocalcaemic patient (answer)ShowHide

A 24-year-old has hypocalcaemia with hyperphosphataemia and a PTH that is high, not low. What is the diagnosis, and what does the PTH tell you? Model: This is pseudohypoparathyroidism — target-tissue resistance to the biological actions of PTH, caused by mutations and/or epigenetic changes at the complex GNAS locus. The elevated PTH is the discriminator: the gland works, the target tissues resist, so calcium stays low and phosphate stays high.^[8] Bone shows only partial PTH sensitivity, so skeletal phenotypes vary (higher bone mineral density in type 1A; decreased bone mass or osteosclerosis in type 1B).^[8]

References17ShowHide

1. [1]Pepe J, Colangelo L, Biamonte F, et al. Diagnosis and management of hypocalcemia Endocrine, 2020.PMID 32367335
2. [2]Mannstadt M, Bilezikian JP, Thakker RV, et al. Hypoparathyroidism Nat Rev Dis Primers, 2017.PMID 28857066
3. [3]Bollerslev J, Buch O, Cardoso LM, et al. Revised European Society of Endocrinology Clinical Practice Guideline: Treatment of Chronic Hypoparathyroidism in Adults Eur J Endocrinol, 2025.PMID 41231236
4. [4]Khan AA, Guyatt G, Ali DS, et al. Management of Hypoparathyroidism J Bone Miner Res, 2022.PMID 36161671
5. [5]Khan S, Khan AA Hypoparathyroidism: diagnosis, management and emerging therapies Nat Rev Endocrinol, 2025.PMID 39905273
6. [6]Clarke BL, Khan AA, Rubin MR, et al. Efficacy and Safety of TransCon PTH in Adults With Hypoparathyroidism: 52-Week Results From the Phase 3 PaTHway Trial J Clin Endocrinol Metab, 2025.PMID 39376010
7. [7]Bobrowicz M, Pachucki J, Popow M Hypomagnesaemia leading to parathyroid dysfunction, hypocalcaemia, and hypokalaemia as a complication of long-term treatment with a proton pump inhibitor - a literature review Endokrynol Pol, 2024.PMID 39279305
8. [8]Wang Y, Lu C, Chen X Variable Bone Phenotypes in Patients with Pseudohypoparathyroidism Curr Osteoporos Rep, 2023.PMID 37014531
9. [9]Shah MK, Kishore P, Shah M, et al. Management of hypoparathyroidism during pregnancy following late maternal diagnosis of DiGeorge syndrome: a case report J Med Case Rep, 2026.PMID 41527007
10. [10]Payne RB, Little AJ, Williams RB, Milner JR Interpretation of serum calcium in patients with abnormal serum proteins Br Med J, 1973.PMID 4758544
11. [11]Payne RB, Carver ME, Morgan DB Interpretation of serum total calcium: effects of adjustment for albumin concentration on frequency of abnormal values and on detection of change in the individual J Clin Pathol, 1979.PMID 429580
12. [12]Lorenzo Sellares V, Torregrosa V Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis) Nefrologia, 2008.PMID 19018742
13. [13]Turner J, Gittoes N, Selby P SOCIETY FOR ENDOCRINOLOGY EMERGENCY ENDOCRINE GUIDANCE: Emergency management of acute hypocalcaemia in adult patients Endocr Connect, 2019.PMID 32022081
14. [14]Edafe O, Antakia R, Laskar N, et al. Systematic review and meta-analysis of predictors of post-thyroidectomy hypocalcaemia Br J Surg, 2014.PMID 24402815
15. [15]Jassam N, Hayden K, Dearman R, et al. Prospective study comparing the outcome of a population-specific adjusted calcium equation to ionized calcium Ann Clin Biochem, 2020.PMID 32340478
16. [16]Coman A, Tarta C, Isaic A, et al. Predictors of Hungry Bone Syndrome After Parathyroidectomy in Secondary Hyperparathyroidism: A Narrative Review of Bone Turnover Biomarkers and Risk Prediction Tools J Clin Med, 2025.PMID 41227247
17. [17]Vuralli D Clinical Approach to Hypocalcemia in Newborn Period and Infancy: Who Should Be Treated? Int J Pediatr, 2019.PMID 31320908